Inhibition of Osteosarcoma metastasis by Insulin-like Growth Factor Binding Protein 5 (IGFBP5)

INTRODUCTION Osteosarcoma (OS) is the most common primary malignancy of bone, with a peak incidence in the second decade of life. Although approximately 80% of patients have either macroor micrometastatic disease at the time of diagnosis, only 10-15% of these lesions can be identified with current imaging modalities. With current treatment regimens, which include wide local resection and chemotherapy, the average five year disease-free survival is only 50-65%. Despite significant advances in surgical techniques and chemotherapeutic regimens over the past few decades, there has been minimal improvement in patient survival. Therefore, there is a critical need to identify molecular markers that provide insight into both the pathogenesis and metastasis of OS.